Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Alzheimer’s Society

    - PMLiVE

    Lilly and Indiana University collaborate to expand clinical trial access

    The five-year agreement includes a focus on R&D for Alzheimer’s disease

    - PMLiVE

    Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

    While the trials did not meet their primary endpoints, they highlighted important biomarker findings

    - PMLiVE

    Vandria announces positive phase 1 data for Alzheimer’s treatment

    Trial data showed that VNA-318 has the ability to penetrate the brain

    - PMLiVE

    UK and US agree on landmark pharma pricing tariff deal

    US tariffs on UK-produced pharmaceuticals will remain at zero for three years

    - PMLiVE

    Eisai submits new drug application for subcutaneous Leqembi in Japan

    LEQEMBI is a treatment for early Alzheimer’s disease

    - PMLiVE

    Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

    The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

    - PMLiVE

    ViiV Healthcare receives NICE recommendation for HIV prevention therapy

    The treatment is the first and only long-acting HIV prevention option available on the NHS in England and Wales

    - PMLiVE

    Pfizer’s Lorviqua recommended by NICE for lung cancer

    Lung cancer is the leading cause of cancer-related deaths worldwide

    - PMLiVE

    Lilly’s early Alzheimer’s disease treatment approved in the EU

    Marketing authorisation follows positive late-stage trial results

    - PMLiVE

    New National Commission launched to strengthen AI regulation

    The Commission will unite healthcare leaders, regulators and technology experts to shape future AI governance

    - PMLiVE

    NHS programme to give head and neck cancer patients fast-track access to mRNA vaccine

    More than 11,000 people are diagnosed with head and neck cancers every year in England

    - PMLiVE

    Eli Lilly’s Alzheimer’s disease drug donanemab recommended by CHMP

    Up to 6.9 million people in Europe are affected by the neurodegenerative disorder

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links